HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Robert M Day Selected Research

apremilast

8/2017Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
8/2017Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
7/2016Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and phase III Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) clinical trials in patients with moderate to severe psoriasis.
5/2016Effects of Apremilast on Pruritus and Skin Discomfort/Pain Correlate With Improvements in Quality of Life in Patients With Moderate to Severe Plaque Psoriasis.
1/2016Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled trials (ESTEEM 1 and ESTEEM 2).
7/2015Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1).
8/2013Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open-label study.
6/2013Novel systemic drugs for psoriasis: mechanism of action for apremilast, a specific inhibitor of PDE4.
5/2013Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study.
8/2012Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Robert M Day Research Topics

Disease

10Psoriasis (Pustulosis Palmaris et Plantaris)
08/2017 - 08/2012
2Pain (Aches)
05/2016 - 05/2013
2Pruritus (Itching)
05/2016 - 05/2013
1Psoriatic Arthritis
08/2017
1Nasopharyngitis
08/2017
1Diarrhea
08/2017
1Inflammation (Inflammations)
08/2012

Drug/Important Bio-Agent (IBA)

10apremilastIBA
08/2017 - 08/2012
4Phosphodiesterase 4 InhibitorsIBA
08/2017 - 05/2013
3Type 4 Cyclic Nucleotide PhosphodiesterasesIBA
07/2016 - 08/2012
1Phosphodiesterase InhibitorsIBA
05/2016
1Biological ProductsIBA
08/2013